When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control the expression of genes, we aim to make a profound difference in patients’ lives. We are advancing a growing pipeline of investigational medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer and monogenic diseases.